- Home
- CLDX vs FTRE Comparison
CLDX vs FTRE Comparison
Compare CLDX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- FTRE
- Stock Information
- Founded
- CLDX 1983
- FTRE 1996
- Country
- CLDX United States
- FTRE United States
- Employees
- CLDX N/A
- FTRE N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FTRE Medical Specialities
- Sector
- CLDX Health Care
- FTRE Health Care
- Exchange
- CLDX Nasdaq
- FTRE Nasdaq
- Market Cap
- CLDX 1.7B
- FTRE 1.4B
- IPO Year
- CLDX 2008
- FTRE N/A
- Fundamental
- Price
- CLDX $22.46
- FTRE $14.88
- Analyst Decision
- CLDX Buy
- FTRE Hold
- Analyst Count
- CLDX 8
- FTRE 11
- Target Price
- CLDX $61.86
- FTRE $23.30
- AVG Volume (30 Days)
- CLDX 774.1K
- FTRE 1.2M
- Earning Date
- CLDX 03-04-2025
- FTRE 03-03-2025
- Dividend Yield
- CLDX N/A
- FTRE N/A
- EPS Growth
- CLDX N/A
- FTRE N/A
- EPS
- CLDX N/A
- FTRE N/A
- Revenue
- CLDX $9,976,000.00
- FTRE $2,975,600,000.00
- Revenue This Year
- CLDX N/A
- FTRE N/A
- Revenue Next Year
- CLDX N/A
- FTRE $1.02
- P/E Ratio
- CLDX N/A
- FTRE N/A
- Revenue Growth
- CLDX 128.55
- FTRE 2.80
- 52 Week Low
- CLDX $20.91
- FTRE $14.27
- 52 Week High
- CLDX $53.18
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- CLDX 42.55
- FTRE 34.60
- Support Level
- CLDX $22.38
- FTRE $14.88
- Resistance Level
- CLDX $23.69
- FTRE $15.83
- Average True Range (ATR)
- CLDX 1.07
- FTRE 0.69
- MACD
- CLDX 0.03
- FTRE 0.08
- Stochastic Oscillator
- CLDX 44.67
- FTRE 25.85
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.